COVID–19 NEWS   Second day of special Parliament sitting to focus on public health issues, action to combat COVID-19 | Hishammuddin to take over SOP compliance announcements from tomorrow - DPM | Workplace clusters record highest COVID-19 cases - Tengku Zafrul | Dewan Rakyat discusses improvements to recovery plan, overcoming of people's hardship | COVID: 207 deaths, highest daily toll to date | 
EXCLUSIVE PRESS

CSOP to Bring CSOP China Healthcare Disruption Index ETF (stock ticker: 3174.HK) to List on the HKEX

21/07/2021 06:07 PM

HONG KONG, July 21 (Bernama) -- CSOP Asset Management Limited (“CSOP”) is proud to announce the listing of CSOP China Healthcare Disruption Index ETF (stock ticker: 3174.HK) on the Hong Kong Stock Exchange (the “HKEX”). 3174.HK will track the performance of the Solactive China Healthcare Disruption Index (the “Index”). With listing price at around HKD 7.8 per unit, trading lot of 100 shares and annual management fee of 0.99%, CSOP China Healthcare Disruption Index ETF will start to trade on 21 July, 2021. Upon inception, 3174.HK has received around HKD 103 million initial investment.

The healthcare sector contains a diverse array of industries, including biotechnology, Internet-based medical services, drug discovery and manufacturing services and many other related services. Since Covid-19 hit the world by surprise, the healthcare sector has received unprecedented attention. In 2018, global spending on health reached USD 8.3 trillion, or 10% of global gross domestic product (GDP). ¹ It is expected to increase at an annual rate of 4.9% from 2018 to 2022, achieving USD 10.05 trillion in 2022. ² Currently, China has the second-largest healthcare industry in the world. Compared to a five-year compound annual growth rate (“CAGR”) of 4% in the United States, China’s healthcare market has grown rapidly at a CAGR of 17%.³ China’s healthcare market size is aimed to expand to about USD 2.4 trillion by 2030. The onset of Covid-19 along with China’s ageing population has further presented considerable growth opportunities for the healthcare sector, particularly in sub-sectors like telemedicine and biotech. Heavily featured in the 13th Five-Year Plan and the Healthy China 2030 strategy, Internet-based healthcare in China has maintained a high CAGR of over 30%. China’s government research & development (“R&D”) spending on biotech topped USD 291 billion in 2019, while companies raised USD 16.5 billion across 90 equity and debt offerings, representing a 17% increase in volume and 13% increase in value from 2018.


Bernama is the trusted source of reliable real-time comprehensive and accurate news for both the public and media practitioners. Our news is published at www.bernama.com ; BERNAMA TV on: Astro Channel 502, unifi TV Channel 631, MYTV Channel 121 IFLIX; and Bernama Radio broadcasting locally on FM93.9 in Klang Valley, Johor (FM107.5), Kota Kinabalu (FM107.9) and Kuching (FM100.9).

Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial

For full news, click here

© 2021 BERNAMA   • Disclaimer   • Privacy Policy   • Security Policy